Diabetes education and treatment adherence

In diabetes, therapeutic education is not simply the transmission of information. It is a structured, continuous, and individualized clinical process through which people acquire the knowledge, practical skills, decision-making ability, and problem-solving tools needed to manage a disease that is treated mainly outside the clinic. Most daily decisions in diabetes are made not by the physician but by the patient and those who support them: when to measure glucose, how to interpret a reading, whether to take or postpone a medication, how to deal with an unexpected meal, how to adapt treatment to physical activity, how to recognize hypoglycemia, how to respond to persistently high values, and how to use a sensor, insulin pen, or pump correctly. Therapeutic education is therefore an integral component of care, not an optional accessory.

The other cornerstone of clinical management is treatment adherence, meaning the extent to which a person’s actual behavior corresponds to the agreed treatment plan. In diabetes, adherence concerns not only taking medications, but also regular monitoring, the quality of injection technique, correct use of devices, the ability to make reasoned self-corrections, attendance at follow-up visits, and persistence over time. The literature shows that structured, repeated education programs improve glycemic control and reduce distress, hypoglycemia, hospital use, and care burden. At the same time, nonadherence remains very common in chronic disease and continues to be a major cause of poor control, apparent treatment failure, inappropriate intensification, and progression of complications in diabetes. This page therefore addresses therapeutic education as the clinical discipline of diabetes self-management, while primary and secondary prevention through diet, body weight, and lifestyle are examined on the dedicated page.

In diabetes, the gap between a theoretical prescription and real life is substantial. A treatment may be correct on paper yet become ineffective if the person has not understood its rationale, cannot use it in practice, fears adverse effects, fails to recognize technical errors, or cannot integrate the care plan into everyday life. This is the clinical value of therapeutic education: transforming an abstract prescription into behavior that is reproducible, understandable, and sustainable. Telling someone that they “must exercise” or “must check their glucose” is not enough. It is necessary to explain when, how, for what purpose, and within which safety limits, and above all to verify that the explanation has truly been understood and can be applied in that person’s specific circumstances.

This requires a change in paradigm. Modern therapeutic education is not based on punitive or paternalistic logic, or on the older concept of “compliance” as passive obedience. Its objective is to develop competent autonomy: the ability to make decisions consistent with treatment goals even when the patient is away from the diabetes team. From this perspective, adherence is not merely faithful execution of orders, but informed participation in a shared pathway. The quality of that participation depends on the therapeutic relationship, clarity of communication, trust, the practical burden of treatment, and alignment between clinical recommendations and real life.

Therapeutic education also differs from generic counseling because it has defined content, measurable objectives, trained professionals, documented processes, and follow-up. A serious program does not merely “explain diabetes”; it teaches people to understand the meaning of glucose values, connect symptoms with data, prevent recurring errors, use technologies, recognize risk situations, manage treatment when everyday routines change, and maintain acquired skills over time. Its effectiveness should not be measured by glycated hemoglobin alone, but also by self-efficacy, reduced distress, problem-solving ability, fewer episodes of severe hypoglycemia, better treatment persistence, and less avoidable use of emergency services.

A further reason why therapeutic education is a treatment in its own right is the increasing complexity of contemporary diabetology. In recent years, diabetes management has expanded to include continuous glucose-monitoring sensors, hybrid automated systems, connected pens, titration algorithms, noninsulin injectable medications, more flexible insulin regimens, and increasingly individualized targets. These innovations can markedly improve outcomes only when accompanied by education, training, and ongoing support. Advanced technology used poorly often causes frustration, unnecessary alarms, interpretation errors, and early discontinuation. Technology selected appropriately and supported by competent education, by contrast, becomes a multiplier of clinical effectiveness.

Finally, therapeutic education should be regarded as treatment because it directly affects the psychological dimensions of the disease. Diabetes imposes continuous cognitive and behavioral tasks, with the risk of decision fatigue, feelings of failure and guilt, avoidance, fear of hypoglycemia, frustration over unmet goals, and diabetes distress. A well-conducted education program reduces isolation, provides interpretive criteria, normalizes certain difficulties, turns errors into useful clinical information, and helps the person perceive treatment as manageable. This has a real impact on continuity of care: a patient who understands more is more likely to persist, whereas a confused, frightened, or overwhelmed patient is more likely to stop, simplify treatment arbitrarily, or use it incorrectly.

An effective therapeutic education pathway begins with a thorough initial assessment of needs, not with the same standardized lesson for everyone. The assessment should define the type and duration of diabetes, current treatment, existing complications, previous exposure to education programs, actual knowledge, practical skills, sensory or motor barriers, health literacy, ability to use numbers and proportions, preferred language, cultural context, meal patterns, work organization, family support, financial resources, beliefs about medications, fears regarding insulin or adverse effects, and the possible presence of depression, anxiety, distress, cognitive impairment, or substance misuse. Without this initial picture, the educational pathway may be theoretically correct but clinically ineffective.

A structured program should have an explicit curriculum, defined objectives, trained professionals, and outcome indicators. Structure does not mean rigidity, but internal coherence. Content should not be improvised during each encounter; it should be organized into progressive modules, adapted to the person, and documented. The literature and guidelines emphasize several constant elements: clear aims, evidence-based content, person-centered educational methods, assessment of learning, program audit, and integration with the rest of the care pathway. The format should also be individualized. Group education can be highly useful by promoting discussion, normalization of experience, and peer support, whereas individual sessions are needed when major language barriers, cognitive disorders, complex technologies, or substantial psychosocial difficulties are present.

Therapeutic education is not a one-time event, but a process that should be reactivated at key points in the clinical course. International recommendations identify four times at which educational needs should be reassessed systematically:

• at diagnosis, when the foundations are laid for understanding the disease and the relationship with the care team;
• annually, and whenever treatment goals are not achieved or difficult-to-interpret glycemic patterns emerge;
• when complicating factors arise, such as new comorbidities, recurrent hypoglycemia, functional deterioration, psychological problems, or the introduction of new treatments;
• during life and care transitions, such as a change of team, change of residence, hospital discharge, transition to new technologies, or major changes in daily routine.

The pathway must also respect the person’s cognitive and practical abilities. Someone with low health literacy may have considerable difficulty understanding labels, dosages, differences among medications, the meaning of targets, or sensor alerts. A person with low numeracy may make errors in carbohydrate calculations, correction factors, insulin-to-carbohydrate ratios, or interpretation of trends and patterns. Teaching should therefore use clear language, logical progression, concrete examples, visual supports, practical exercises, and active verification. Understanding should never be assumed, especially in people who nod politely but are then unable to repeat or demonstrate what was discussed.

Finally, a truly structured program must be integrated into the overall clinical pathway. The diabetologist, general practitioner, nurse, dietitian, educator, psychologist, and other professionals involved should provide consistent messages. When patients receive conflicting instructions, the likelihood of nonadherence rises rapidly. The education pathway must therefore not remain isolated, but should communicate with pharmacological treatment, monitoring, prevention of complications, and management of transitions. Telemedicine and digital formats can also be highly useful in this framework, provided they do not mechanically replace the clinical relationship but make it more accessible, continuous, and timely.

Essential educational content is not a theoretical review of pathophysiology, but what the person needs to know and do in order to live safely and achieve better clinical outcomes. The first domain is practical understanding of the disease: what it means to have diabetes, which goals are realistic, why targets are individualized, how to distinguish an isolated value from a persistent pattern, which factors explain glycemic variability, why symptoms and numbers do not always agree, and why treatment requires adjustment over time. It is not enough to know that “high glucose is harmful”; people need to understand how chronic control, variability, hypoglycemia, and prolonged fluctuations affect target organs and treatment decisions.

The second domain is monitoring. The person must know how to use the tools correctly, understand their limitations, interpret readings in context, and link them to an action. For capillary self-monitoring, this means knowing when to test, how to perform the measurement correctly, and how to interpret the result in relation to meals, exercise, symptoms, and treatment. For continuous glucose monitoring, it means understanding trend arrows, time in range, exposure to hypoglycemia, nocturnal patterns, the physiological lag between interstitial and capillary glucose, and the circumstances in which it is prudent to confirm a sensor value with a capillary measurement, particularly when symptoms and sensor data do not agree.

A third domain concerns medications. Every person should know not only the name of the treatment, but also its clinical role, the correct time of administration, common errors, expected adverse effects, warning signs, interactions with meals and exercise, and the consequences of stopping it arbitrarily. This applies to oral medications, noninsulin injectable therapies, and insulin. Education must be especially rigorous for treatments that can cause hypoglycemia, such as insulin and secretagogues, because poor understanding can produce two opposite and equally harmful outcomes: actual hypoglycemia on one hand, and chronic underdosing driven by fear on the other.

A fourth domain is problem solving. Diabetes cannot be managed well by following identical rigid rules every day, because real life continually introduces deviations: different schedules, unexpected meals, stress, intercurrent illness, shift work, travel, occasional or unplanned exercise, changes in appetite, technical problems with sensors or infusion, missed doses, and treatment changes. Therapeutic education must therefore teach not only standard procedures but also simplified clinical reasoning: recognizing a problem, interpreting its probable cause, understanding when it can be managed independently, and knowing when the care team should be contacted.

A fifth domain is risk reduction. This includes early recognition of hypoglycemia and hyperglycemia, immediate management of episodes, prevention of recurrence, driving safety, inspection of injection sites, foot care, continuity of periodic assessments, awareness of recommended vaccinations, and attention to symptoms requiring medical evaluation. In a well-organized program, this content is not delivered all at once, but distributed over time according to clinical priority and learning capacity.

The National Standards for Diabetes Self-Management Education and Support (DSMES) also identify eight core areas that each pathway should address in proportion to individual needs.

DSMES areas

• understanding the disease process and treatment options;
• healthy eating and meal management;
• physical activity and its metabolic effects;
• correct medication use;
• monitoring and interpretation of glucose data;
• prevention of complications and risk reduction;
• problem solving in everyday and unexpected situations;
• healthy coping, meaning emotional management and psychological adaptation to the disease.

These domains should be adjusted over time. A newly diagnosed person primarily needs basic interpretive skills and immediate safety, whereas someone who has lived with diabetes for years may need a technical update, treatment review, work on burnout, management of complex patterns, or retraining in techniques that appeared to have been learned but have deteriorated. Therapeutic education is therefore not a school course completed once and for all; it is a clinical resource to be reactivated and readapted throughout the course of the disease.

To address the problem correctly, it is useful to distinguish adherence from persistence. Adherence describes how closely actual behavior matches the agreed regimen in dose, timing, frequency, technique, and regularity. Persistence refers to continuity over time: how long the patient continues treatment without interruption. In diabetes, departures from the plan take many forms. Some people never start a prescribed treatment; some start but take it intermittently; some reduce doses on their own; some formally continue treatment but use an incorrect injection technique; some measure glucose without knowing how to interpret it; some use a sensor but systematically ignore its alerts; some attend follow-up rarely; some secretly stop a medication because of adverse effects or cost; and some appear fully adherent on paper while making numerous practical errors.

Nonadherence can almost never be explained by a single cause. The most useful model is multidimensional and includes factors related to the healthcare system, treatment, disease, socioeconomic context, and the individual. Healthcare-system factors include poor access to education programs, short consultations, contradictory messages, lack of follow-up, ineffective referral processes, costs, logistical difficulties, and fragmented care. Treatment-related factors include regimen complexity, number of administrations, adverse effects, frequent monitoring requirements, handling of devices, the cost of medications and supplies, fear of hypoglycemia, weight gain, gastrointestinal symptoms, problems storing or transporting insulin, and the cumulative fatigue of making many decisions every day.

Disease-related factors are also important. Diabetes often remains minimally symptomatic for years, reducing the immediate perception of treatment benefit, particularly when the regimen is burdensome and the advantage appears delayed. Conversely, frequent hypoglycemia or marked glycemic variability can produce maladaptive learning: the patient reduces or skips doses to avoid the feared event, obtaining immediate relief while worsening overall control. In people with long-standing disease, fatigue, burnout, decision saturation, and a sense of failure further increase the likelihood of intermittent adherence.

Personal and psychosocial factors are often decisive. Important examples include low health literacy, numeracy difficulties, language barriers, misconceptions about medications, poor confidence in treatment, fear of insulin, needle anxiety, depression, anxiety disorders, diabetes distress, eating disorders, cognitive impairment, visual problems, reduced manual dexterity, harmful alcohol use, shift work, financial insecurity, lack of family support, and social stigma. In some cases nonadherence is intentional and results from a conscious, although clinically harmful, decision. In others it is unintentional and stems from forgetfulness, confusion, overload, unclear instructions, or practical obstacles.

A common clinical error is to attribute poor glycemic control automatically to patient nonadherence. An elevated HbA1c may also result from an inadequate regimen, clinician therapeutic inertia, poorly individualized targets, unrecognized incorrect injection technique, injection-site lipodystrophy, improper device use, or misunderstanding of monitoring data. Adherence must therefore be explored methodically and without judgment, avoiding accusatory language. The objective is not to decide whether the patient is “good” or “bad,” but to identify where the treatment chain breaks down and why.

Assessment of adherence cannot be reduced to a generic question such as “Do you take your treatment correctly?” Most people give a socially desirable answer, especially if they fear judgment or blame. A targeted, nonjudgmental interview is needed to explore what actually happens in everyday life: how many doses are missed or delayed, at which times, under what circumstances, with which symptoms, fears, and practical obstacles. Normalizing questions are often the most useful because they make honest answers possible: many people find it difficult to follow treatment all the time—what happens in your case; on which days is it hardest; which steps feel most burdensome; which part of the treatment creates the most uncertainty; and which adverse effects or inconveniences sometimes lead you to avoid a medication.

Objective evidence should complement the interview. In diabetes, useful sources include glucose profiles, continuous-monitoring downloads, insulin-pump or connected-pen data, prescription-refill history where available, discrepancies between reported doses and glycemic patterns, unexpected hypoglycemia, or recurrent hyperglycemia at times suggestive of missed doses. No single indicator is sufficient, however. A sensor used intermittently or interpreted incorrectly can produce misleading data, and elevated HbA1c may reflect not only missed treatment but also technical errors or a regimen that is no longer appropriate.

Practical assessment of skills is essential. Patients should demonstrate how they prepare and administer insulin, select and rotate sites, store devices, respond to a sensor alert, treat hypoglycemia, correct a high value, interpret a trend arrow, and take medications in relation to meals. Direct observation often identifies problems that do not emerge from conversation alone: repeated use of the same injection area, incorrect needle angle, inappropriate timing relative to meals, excessive needle reuse, failure to inspect sites, poor device hygiene, or misunderstanding of differences among insulins or medications with distinct mechanisms.

Inspection of injection sites is a full component of technical-adherence assessment. Lipohypertrophy or other local abnormalities can cause irregular absorption, marked glycemic variability, unexplained hypoglycemia, and apparent insulin inefficacy. If they are not actively sought, clinicians may interpret the picture as nonadherence or a need to increase doses, further worsening the situation. In insulin-pump users, infusion sites, change frequency, occlusion problems, unrecognized interruptions, and understanding of the actions required when delivery failure is suspected should likewise be assessed.

A complete evaluation should also include health literacy, numeracy, psychological burden, social support, and economic factors. A person may be motivated but unable to understand a complex regimen; another may understand perfectly but be unable to afford it; another may have good technical skills but be blocked by anxiety, fear of hypoglycemia, or distress. Guidelines also recommend periodic screening for diabetes distress, at least annually and during transitions or when goals are not met. This is crucial because distress is associated with lower adherence, poorer glycemic control, reduced confidence in self-management, and greater avoidance of daily tasks.

Finally, the assessment should distinguish what the patient knows, what the patient can do, and what the patient can sustain over time. Theoretical knowledge, practical competence, and behavioral persistence are different dimensions. A person may know exactly what should be done but be unable to do it consistently; another may be adherent but rely on inappropriate routines learned years earlier; another may maintain good medication adherence while having major gaps in data interpretation or prevention of acute episodes. Only this multidimensional view allows a genuinely useful intervention to be designed.

The most effective strategies are not generic appeals to discipline, but interventions that reduce the gap between treatment complexity and the person’s actual capacity to sustain it. The first requirement is individualization. The more a plan reflects schedules, eating habits, financial resources, preferences, fears, educational background, work, family support, and patient priorities, the more likely it is to be followed. A theoretically perfect regimen that is incompatible with daily life often leads to discontinuation or arbitrary adaptations.

A second cornerstone is the use of structured behavioral techniques. Motivational interviewing, shared definition of realistic goals, problem solving, specific action plans, review of encountered barriers, and positive reinforcement are more effective than purely didactic teaching. Goals should be concrete and verifiable: not “monitor better,” but, for example, rotate injection sites according to an agreed plan, check glucose systematically before driving, treat hypoglycemia using the correct procedure, review sensor patterns with the team once a week, or take a medication at a consistent time linked to a stable daily routine.

The DSMES literature reports more consistent results when interventions are behavior-focused, adapted to individual needs, delivered by a multiprofessional team, and provide sufficient educational exposure over time. Sessions that are too brief, isolated, or purely lecture-based tend to produce modest and less durable benefits. Distributed education with later reinforcement and opportunities to review errors arising in everyday practice is much more effective at building stable skills. This is particularly true for people starting or intensifying insulin, transitioning to new technologies, or experiencing complex glycemic patterns.

Another key lever is simplification. Improving adherence often means reducing unnecessary complexity: using more sustainable regimens, selecting easier-to-handle devices, avoiding contradictory instructions, simplifying language, providing clear written guidance, reducing calculation burden where possible, anticipating likely adverse effects and explaining how to manage them, and clarifying in advance what to do after a missed dose or an unexpected event. Many treatment interruptions occur not because of ideological rejection, but because patients were not prepared for the first practical obstacles.

The relational dimension is equally decisive. People adhere better when they feel the team listens, does not judge, and turns difficulties into useful clinical information rather than blame. This approach encourages honesty about the actual number of missed doses, adverse effects, fears, and compensatory behaviors. A known problem is much easier to correct than a hidden one. Peer support, community health workers, informed caregivers, and telehealth solutions can likewise improve continuity and access, especially for vulnerable people or in areas with fewer services.

A final key strategy is to address structural determinants of nonadherence. Intensifying education is of little value if the patient cannot obtain needles, sensors, or medications; must choose which prescriptions to purchase; cannot reach the clinic; works shifts that are incompatible with the agreed plan; or lives in circumstances that make even minimal regularity impossible. Good therapeutic education therefore includes identifying and, where possible, removing organizational, economic, and social barriers. When this step is omitted, responsibility is often shifted to the patient even though the failure is actually systemic.

In diabetes, a substantial proportion of nonadherence arises from technical errors. Therapeutic education must therefore devote specific attention to the correct use of medications and devices. For noninsulin therapies, patients should understand the rationale for the medication, the best time to take it, its relationship to meals where relevant, its principal adverse effects, and how to manage them without stopping treatment arbitrarily. A patient who stops metformin at the first gastrointestinal symptom, discontinues a glucagon-like peptide-1 (GLP-1) receptor agonist because of nausea without understanding the rationale for titration, or uses a sodium-glucose cotransporter 2 (SGLT2) inhibitor incorrectly because dehydration warning signs and higher-risk settings have not been explained has not received adequate preparation.

Insulin requires even more rigorous training. Explaining the number of units is not enough. Education must cover differences among insulin preparations, the relationship between injection timing and meals when relevant, interpretation of glucose values for titration, prevention and treatment of hypoglycemia, what to do after a missed dose, correct storage, disposal of materials, and above all injection technique. Recent literature on injection technique shows how clinically important the quality of the procedure is: selecting the site, systematically rotating areas, avoiding repeated use of the same location, using a pen or syringe correctly, employing skinfolds when indicated, and inspecting the skin periodically. Apparently minor errors can produce irregular absorption, wide glycemic variability, and a false impression that insulin is ineffective.

Injection-related lipodystrophy, particularly lipohypertrophy, deserves specific attention. If a patient continues injecting into thickened areas, absorption becomes unpredictable and may alternate between functional underdosing and unexpected hypoglycemia. This phenomenon is frequently underestimated and may be mistaken for “brittle diabetes” or global nonadherence when the actual problem is technical. Education should therefore include periodic inspection and palpation of sites, rational rotation, recognition of areas to avoid, and explanation of the relationship between skin changes and metabolic control.

Technology also requires specific competencies. Continuous glucose-monitoring systems improve outcomes only when patients know how to interpret them. This means understanding time in range, time below range, trend arrows, the distinction between a single reading and a recurring pattern, situations in which symptoms and data disagree, and technical limitations of the device. Similarly, an insulin pump or hybrid automated system requires training in infusion sets, replacement of supplies, response to occlusions or disconnections, bolus management, event review, prevention of unrecognized interruptions, and early recognition of situations in which a technical problem can rapidly cause hyperglycemia and ketosis.

The cognitive burden of technology must also be considered. A sensor with numerous alerts can improve safety but may cause alarm fatigue, hypervigilance, anxiety, or avoidance in some people. A connected pen can be very useful for dose tracking but requires digital familiarity. An automated system can reduce decision burden but must be understood rather than used as a black box. Device selection should therefore take account not only of technical performance, but also of age, practical abilities, willingness to train, expectations, and long-term sustainability. No technology performs optimally without education, competency assessment, and ongoing support.

Among the most underestimated determinants of adherence are health literacy and numeracy. Health literacy is the ability to find, understand, and use health information and services; numeracy is the ability to manage quantities, proportions, calculations, and numerical data. Both are critical in diabetes because patients must read labels, understand targets, interpret graphs, manage carbohydrate-to-insulin relationships, distinguish correction from meal coverage, evaluate a trend arrow, recognize the severity of hypoglycemia, and apply instructions that may be complex. A well-intentioned person with poor numeracy can make serious errors without realizing it.

Therapeutic education should therefore be designed with clear language, reduced unnecessary complexity, concrete examples, visual materials, practical exercises, and active verification of understanding. Messages should be progressive, consistent, and repeated at key times. Systematic reviews show that interventions designed to improve health literacy can translate into better glycemic control and self-management behavior. This is particularly important for patients who appear “nonadherent” but have never truly understood what is expected of them.

The emotional dimension is equally decisive. Diabetes distress is not the same as major depression, although the two may coexist. It is the specific burden of living with a disease that demands continuous attention, numerous microdecisions, fear of complications, effort to maintain demanding routines, and a sense of failure in the face of imperfect data. As distress increases, adherence tends to deteriorate: people avoid measurements that provoke anxiety, miss appointments, postpone reviewing data, become less consistent with treatment, eat in a more disorganized way, and progressively abandon the most burdensome tasks.

The team must therefore create space for these dimensions to emerge. Asking whether the patient feels overwhelmed, fears hypoglycemia, experiences the sensor as helpful or alarming, feels guilty about the numbers, is embarrassed to inject in public, or perceives treatment as limiting personal identity is not a psychological luxury but an integral part of diabetes medicine. Once these issues are recognized, targeted education, psychological support, coping strategies, peer support, and recalibration of goals become possible.

Social support has an equally powerful influence on outcomes. Informed relatives, competent caregivers, understanding workplaces, and community networks can substantially facilitate continuity of treatment. Conversely, isolation, family conflict, insecurity, stigma, and lack of a support network make any care plan much more fragile. Good therapeutic education is therefore not directed at an abstract individual alone, but considers the relational context in which treatment must be lived and sustained.

A very common error is to consider the educational task complete after the initial instructions have been given. Learning in diabetes erodes over time and is disrupted by daily routines, treatment changes, deterioration of practical technique, and emotional saturation. Educational follow-up is therefore essential. Every clinical visit should include at least a brief reassessment of educational needs, technical accuracy, reported adherence, and problems encountered in real life. During more complex phases, dedicated reinforcement sessions are required because a routine medical visit is rarely sufficient.

The outcomes of an education program should not be interpreted simplistically. Glycated hemoglobin remains important, but it is not the only indicator and is sometimes not the most timely. A high-quality pathway should also consider time in range for sensor users, clinically significant hypoglycemia, reductions in urgent-care use, correct injection technique, regularity of follow-up, treatment persistence, quality of data interpretation, self-efficacy, perceived distress, treatment satisfaction, ability to solve recurring problems, and reduction of preventable errors.

It is useful to consider outcomes at four levels. The first is clinical, including HbA1c, glycemic patterns, acute events, and safety. The second is behavioral: what the person actually does, such as taking medications, rotating sites, using the sensor appropriately, managing hypoglycemia, and attending follow-up. The third is experiential and concerns well-being, perceived burden, confidence in self-management, and reduced distress. The fourth is organizational, including access to the program, continuity of the pathway, quality of documentation, and integration with the rest of the team.

Follow-up should also be flexible. Some patients need close contact when starting a new treatment or after hospital admission; others benefit from telemonitoring, brief review of downloads, or telephone support; still others mainly need periodic reassessment of injection sites and psychological burden. There is no single correct format. There is, however, one general principle: whenever the clinical history changes, educational needs must be reopened rather than assumed to have been permanently met.

In practice, the success of a good program is not numerical perfection, but safer, more consistent, more informed, and more sustainable management. A patient who can recognize errors, correct them, seek help in time, and maintain treatment continuity is clinically better protected than someone who has received extensive information but has not developed stable skills. Therapeutic education is therefore a form of complication prevention and also a means of humanizing care, because it restores an active and competent role to the patient.

The consequences of inadequate therapeutic education are not limited to a higher HbA1c. A poorly trained or nonadherent patient is more exposed to wide glycemic fluctuations, recurrent hypoglycemia, persistent hyperglycemia, correction errors, inappropriate medication use, arbitrary discontinuation, avoidable emergency-department visits, admissions for metabolic decompensation, and delayed recognition of important technical or clinical problems. In some situations, educational failure can contribute directly to serious acute events, such as severe hypoglycemia or hyperglycemic crises, particularly when the person cannot recognize warning signs early or has not internalized simple but decisive procedures.

In the medium and long term, nonadherence worsens overall metabolic control, promotes progression of microvascular and macrovascular complications, increases the burden of disease on the healthcare system, and may generate a vicious cycle of treatment intensification that is not always appropriate. If the clinician wrongly interprets a problem of technique, understanding, or persistence as “medication failure,” additional therapies may be prescribed or doses increased without correcting the true cause of poor control. The result is greater complexity, cost, and burden and, paradoxically, lower adherence.

There are also less visible but highly important consequences: loss of confidence, burnout, feelings of inadequacy, progressive disengagement from the team, avoidant use of the sensor, fewer follow-up visits, abandonment of realistic goals, and poorer quality of life. In this situation the patient not only stops following a treatment plan, but progressively stops feeling capable of managing the disease. This is the deepest target of well-designed therapeutic education: not only to improve numbers, but to prevent diabetes from becoming a sequence of perceived failures.

For all these reasons, assessment of adherence and self-management competence should be a routine component of every diabetes-care pathway. When targets are not reached, patterns are inconsistent, unexpected hypoglycemia occurs, a technology is introduced, or the disease enters a new phase, the correct clinical question is not only which medication to add, but also what the person has truly understood, what they can do, what they can sustain, and which concrete obstacles prevent them from doing it.